The term “stem cell,” stammzellen, was first used in 1868 by the German biologist Ernst Haeckel to describe the original, unicellular progenitor from which Dr. Haekel supposed all multicellular plant and animal life might have descended.
Tag Archive: Cancer
Established in 2001, the Commonwealth Universal Research Enhancement (CURE) program awards grants to biomedical, clinical, and health services research projects.
Kids who survive cancer may face a variety of physical and emotional challenges as a result of their treatment. One of these is the possibility of infertility following cancer treatment.
Proton therapy, which uses high-energy subatomic particles, may offer a precise, organ-sparing treatment option for children with high-risk forms of neuroblastoma, the most common solid tumor of early childhood.
Children’s Hospital investigators may have developed a completely new type of cancer immunotherapy, one that involves harnessing the body’s immune system to attack tumors.
Yesterday, CBS Sunday Morning featured a story on the anaplastic lymphoma kinase, or ALK, clinical trial for lymphoma and neuroblastoma and CHOP’s partnership with the Alex's Lemonade Stand Foundation, which supported the basic research.
A physician-researcher from The Children’s Hospital of Philadelphia will lead the first-ever pediatric “Dream Team” solely focused on creating new treatments for the most challenging childhood cancers.
Tom Curran, PhD, FRS, Deputy Scientific Director of The Children’s Hospital of Philadelphia Research Institute, will be formally inducted into the AACR Academy on April 5 in Washington, D.C.
CHOP’s Peter Adamson, MD, who heads the Children’s Oncology Group, the largest organization in the world dedicated to childhood and adolescent cancer research, was recently interviewed by journalist Paul Goldberg for the March 15 issue of The Cancer Letter.
A recent genomic study of neuroblastoma reinforces the challenges of treating the most aggressive forms of this disease. Contrary to expectations, the researchers found relatively few recurrent gene mutations — mutations that would suggest new targets for neuroblastoma treatment. Instead, the investigators have refocused on how neuroblastoma tumors evolve in response to medicine and other factors.